Arnold Ventures submitted feedback on the FDA’s draft guidance for expedited programs supporting accelerated approval of drugs and biologics. The organization emphasized the importance of rigorous randomized controlled trials and timely confirmatory studies to ensure surrogate endpoints translate into meaningful clinical benefits for patients. Arnold Ventures advocates for evidence-based policies that improve health care affordability and quality.
